Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03239834
Other study ID # VIG-001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 7, 2017
Est. completion date December 20, 2020

Study information

Verified date August 2021
Source Vigilant Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objectives Validate the OncAlert® RAPID Test by demonstrating that NPV > (1 -prevalence). Evaluate the independent and associated contribution of readily available clinical variables including age, race, gender, HPV status, socioeconomic level, tobacco, and alcohol use with the biopsy and test results. Evaluate OncAlert® RAPID Test results in patients without immediate biopsy, both at baseline and scheduled follow-up visit (approximately 1-3 months±14 days), to assess impact on outcome. Planned Number of Subjects A total enrollment of up to 1000 individuals is projected with 600 as the minimum accrued. Patients in the primary cohort (1a and 1b) will be followed until pathology of clinically directed incisional / diagnostic biopsy pathology report is received. Up to 200 'non-biopsy subjects' will be followed during a 1-3 month ±14 days clinic visit. Patient Population Cohorts 1a and 1b: Subjects with a clinical suspicion of oral potentially malignant disorders, oral or oropharyngeal cancer, or both based in part on clinical examination, symptoms, clinical history, suspicious lesion(s) in mouth without history of a prior positive biopsy. Even if the suspicion is low for cancer or precancer, the patient is eligible if a biopsy is performed, in part, to rule this out. For example, if a subject has findings on imaging, or worrisome localizing symptoms in the oral cavity or oropharynx, they would be eligible. In addition, subjects with papillomas or other findings where there is a low level of concern, but cancer is still in the differential, are also eligible. - Cohort 1a: oral cavity - Cohort 1b: oropharynx Cohort 2: Subjects are enrolled with a clinical suspicion of oral potentially malignant disorders, oral or oropharyngeal cancer, or both based in part on clinical examination, symptoms, clinical history, suspicious lesion(s) in mouth without history of a prior positive biopsy; however, based on clinical impression and or patient related issues no immediate biopsy is obtained. Screen Fail Rate: A 20% Screen Fail Rate is anticipated. Investigational Product Name: OncAlert Oral Cancer RAPID Test (OncAlert RAPID) Methodology Overview Prospectively collect 5cc of normal saline after a combination of swish, gargle and spit into the provided collection specimen cup. Specimens will be collected at baseline (time of biopsy) as per standard practice at each site. The OncAlert RAPID Test cassette is inserted into the specimen cup and read directly from the cassette in 10 minutes. In addition, comprehensive clinical - pathology and patient demographic features including age, gender, race, ethnicity, and all pathology biopsy results will be collected. Any pertinent additional clinical data including HPV status, socioeconomic status, smoking, drinking history, and pertinent features related to oral health will be obtained. A central pathology review for all biopsy results will be performed and incorporated into the final analyses.


Description:

Overview The OncAlert Oral Cancer RAPID Test (OncAlert RAPID) is a qualitative point-of-care lateral flow assay to aid in the decision to biopsy in patients with clinical features associated with oral potentially malignant disorders and or oral/oropharyngeal cancer (i.e. head and neck squamous cell carcinoma). Proposed Intended Use Statement The device measures soluble CD44 and total protein in saliva samples collected in saline. The test is an adjunct to the biopsy decision process, and not intended as a screening or stand-alone diagnostic assay. To be used in adults 23 years and older. Not intended for use in pregnant women. STUDY OBJECTIVES The principal objectives of this study are to: - Validate the OncAlert RAPID Test, with an NPV ≥ (1-prevalence), - Evaluate OncAlert RAPID Test results in patients without immediate biopsy, both at baseline and scheduled follow-up visit (approximately 1-3 months), to assess impact on outcome, - Evaluate the independent and associated contribution of readily available clinical variables including age, race, gender, HPV status, socioeconomic level, tobacco, and alcohol use with the biopsy and test results. STUDY OVERVIEW Study Approach Prospectively collect 5cc of normal saline after a combination of swish, gargle and spit into the provided collection specimen cup. 1cc will be removed and sequestered for subsequent downstream analyses (Section 7). Specimens will be collected at baseline (time of biopsy) as per standard practice at each site. The OncAlert RAPID Test cassette is inserted into the specimen cup and read directly from the cassette in 10 minutes. In addition, acquire comprehensive clinical - pathology and patient demographic features including age, gender, race, ethnicity, and all pathology biopsy results. Also, obtain any pertinent additional clinical data including HPV status, socioeconomic status, smoking, drinking history, and pertinent features related to oral health. It is presumed that some patients within the current biopsy protocol will undergo treatment as a result of the biopsy diagnosis. The clinical-pathology data, when accessible, for these patients will be collected for subsequent secondary analyses. A central pathology review for all biopsy results will be performed and incorporated into the final analyses. Study Duration For Cohorts 1a and 1b patients, the pathology results of clinically directed incisional / diagnostic biopsy will be followed until finalized and received. Cohort 2 patients not having an initial incisional / diagnostic biopsy at the initial visit will have an additional OncAlert® RAPID test performed within 1 -3 months±14 days (or as defined by standard of care (SOC)after the initial visit.) The study will conclude after all data is collected and analyzed. This could vary from 12 to 36 months or more depending on accrual rates at the open sites and other factors.


Recruitment information / eligibility

Status Completed
Enrollment 893
Est. completion date December 20, 2020
Est. primary completion date August 24, 2020
Accepts healthy volunteers No
Gender All
Age group 23 Years and older
Eligibility Inclusion Criteria: - 23 years of age or older - A clinical suspicion of oral potentially malignant disorders, oral or oropharyngeal cancer, or both based in part on clinical examination, symptoms, clinical history, suspicious lesion(s) in mouth without history of a prior positive biopsy. - The subject must be able to comprehend and sign an approved Informed Consent Form and other applicable study documents. - Patients are eligible regardless of race, gender, and ethnicity Exclusion Criteria: - Prior history and/or diagnosis of any HN cancer/HNSCC of the oral cavity, oropharynx, or hypopharynx including nasopharyngeal carcinoma. - Prior treatment of HN cancer / HNSCC of the oral cavity, oropharynx, or hypopharynx including nasopharyngeal carcinoma. - Prior history of a positive biopsy of the oral cavity or oropharynx. - Planned excisional biopsy for a pathology diagnosis of HNSCC - Clinical presentation without localizing findings - Prior history of a salivary gland tumor - Current and or prior diagnosis of cancer (note: other than basal and squamous cell carcinoma of the skin) within the past 5 years. - Pregnant

Study Design


Intervention

Device:
OncAlert
A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.

Locations

Country Name City State
United States University of Maryland Baltimore Maryland
United States Specialty Physician Associates Bethlehem Pennsylvania
United States Dr. Joel Epstein Beverly Hills California
United States Boston University Dental School Boston Massachusetts
United States Tufts University Boston Massachusetts
United States Medical University of South Carolina Charleston South Carolina
United States Chicago ENT Chicago Illinois
United States Heartland Medical Research Clive Iowa
United States Duke Head and Neck Surgery & Communication Services Durham North Carolina
United States UConn Dental Medicine Farmington Connecticut
United States Fort Worth ENT Fort Worth Texas
United States Eastern Carolina University School of Dental Medicine Greenville North Carolina
United States UMKC School of Dentistry Kansas City Missouri
United States Biosolutions Clinical Research Center La Mesa California
United States Loma Linda School of Dentistry Loma Linda California
United States Tower ENT, based at Cedars Sinai Medical Center Los Angeles California
United States Berkson Medical, LLC Mansfield Texas
United States University of Tennessee Memphis Tennessee
United States University of Miami Health Systems Miami Florida
United States ENT of South Florida Plantation Plantation Florida
United States ENT of South Florida Port St. Lucie Port Saint Lucie Florida
United States Sacramento ENT Roseville California
United States Sacramento ENT Sacramento California
United States Chrysalis Clinical Research Saint George Utah
United States Asclepes Research Weeki Wachee Florida
United States Piedmont Ear, Nose and Throat Associates Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Vigilant Biosciences, Inc. Pearl Pathways

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Association of RAPID results with oral cavity / oropharyngeal biopsy. The likelihood of a positive biopsy was determined when either the presence of a CD44 band or Total Protein above a specific gradient were positive. 18 months
Primary Association of RAPID results with the clinical decision process for avoiding an immediate biopsy. Evaluate OncAlert RAPID results in patients without immediate biopsy, both at baseline and repeat results at scheduled follow-up visit (approximately 1-3 months). If biopsy performed associate RAPID positive vs. negative results with biopsy outcome. If not biopsy is performed, compare results with clinical decision for not to biopsy. 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT00251381 - Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. Phase 2
Completed NCT03074110 - Isocapnic Hyperventilation - an Alternative Method N/A
Enrolling by invitation NCT04266093 - Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Recruiting NCT02792322 - Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck N/A
Active, not recruiting NCT00918710 - Human Papillomavirus and Oropharynx Carcinoma N/A
Recruiting NCT05412628 - Investigating the Association Between Microbiota and Esophageal/Oropharyngeal Cancer N/A
Recruiting NCT04124198 - Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma N/A
Completed NCT00721799 - F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients Phase 2
Recruiting NCT00181038 - Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery Phase 3
Terminated NCT04015336 - E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer Phase 2
Withdrawn NCT04044950 - A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer Phase 2
Completed NCT02262247 - A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures N/A
Terminated NCT01687413 - Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Phase 3
Completed NCT01530997 - De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca Phase 2
Completed NCT03077243 - P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC Phase 2
Completed NCT03010813 - A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery N/A
Terminated NCT02045186 - Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) N/A
Withdrawn NCT02298595 - Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT02281955 - De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study Phase 2
Terminated NCT01525927 - Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity Phase 2